![Andrew Walton-Green](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Andrew Walton-Green
Président chez Biosceptre (Aust) Pty Ltd.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Currie Gavin | M | - |
Biosceptre (Aust) Pty Ltd.
![]() Biosceptre (Aust) Pty Ltd. Pharmaceuticals: MajorHealth Technology Biosceptre (Aust) Pty Ltd. develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer. The company was founded in 2000 and is headquartered in North Ryde, Australia. | - |
Simon John Peat | M | 51 |
Project Better Energy Ltd.
![]() Project Better Energy Ltd. Electric UtilitiesUtilities Project Better Energy Ltd. is a British company that generates electric power. The private company is based in Burton-on-Trent, UK. and has subsidiaries in United Kingdom. Project Better Energy was founded in 2012. | - |
Michael Lovett | M | - |
Biosceptre International Ltd.
![]() Biosceptre International Ltd. BiotechnologyHealth Technology Part of Biosceptre (Aust) Pty Ltd., Biosceptre International Ltd. is a biopharmaceutical company based in Babraham, UK. The British company is focused on developing their BRiDGECAR™ system, which combines nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies. The company's researchers are pioneers in cancer therapeutic development, with a vision of targeted treatment for millions of cancer patients across the world. The company's multi-targeted BRiDGECAR™ system has the potential to benefit a range of malignancies and make a drastic difference to the lives of millions of cancer patients. The company's advisory board includes Sir Gregory Winter, a 2018 Nobel Prize winner in Chemistry.
Biosceptre (Aust) Pty Ltd.
![]() Biosceptre (Aust) Pty Ltd. Pharmaceuticals: MajorHealth Technology Biosceptre (Aust) Pty Ltd. develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer. The company was founded in 2000 and is headquartered in North Ryde, Australia. | - |
Jon Collins | M | - |
Biosceptre (Aust) Pty Ltd.
![]() Biosceptre (Aust) Pty Ltd. Pharmaceuticals: MajorHealth Technology Biosceptre (Aust) Pty Ltd. develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer. The company was founded in 2000 and is headquartered in North Ryde, Australia.
Biosceptre International Ltd.
![]() Biosceptre International Ltd. BiotechnologyHealth Technology Part of Biosceptre (Aust) Pty Ltd., Biosceptre International Ltd. is a biopharmaceutical company based in Babraham, UK. The British company is focused on developing their BRiDGECAR™ system, which combines nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies. The company's researchers are pioneers in cancer therapeutic development, with a vision of targeted treatment for millions of cancer patients across the world. The company's multi-targeted BRiDGECAR™ system has the potential to benefit a range of malignancies and make a drastic difference to the lives of millions of cancer patients. The company's advisory board includes Sir Gregory Winter, a 2018 Nobel Prize winner in Chemistry. | - |
Patrick Schlegel | M | - |
Biosceptre (Aust) Pty Ltd.
![]() Biosceptre (Aust) Pty Ltd. Pharmaceuticals: MajorHealth Technology Biosceptre (Aust) Pty Ltd. develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer. The company was founded in 2000 and is headquartered in North Ryde, Australia. | - |
Ronald Stafford Watts | M | - |
Biosceptre International Ltd.
![]() Biosceptre International Ltd. BiotechnologyHealth Technology Part of Biosceptre (Aust) Pty Ltd., Biosceptre International Ltd. is a biopharmaceutical company based in Babraham, UK. The British company is focused on developing their BRiDGECAR™ system, which combines nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies. The company's researchers are pioneers in cancer therapeutic development, with a vision of targeted treatment for millions of cancer patients across the world. The company's multi-targeted BRiDGECAR™ system has the potential to benefit a range of malignancies and make a drastic difference to the lives of millions of cancer patients. The company's advisory board includes Sir Gregory Winter, a 2018 Nobel Prize winner in Chemistry. | - |
Colin Wood | M | 56 |
Project Better Energy Ltd.
![]() Project Better Energy Ltd. Electric UtilitiesUtilities Project Better Energy Ltd. is a British company that generates electric power. The private company is based in Burton-on-Trent, UK. and has subsidiaries in United Kingdom. Project Better Energy was founded in 2012. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Christopher Errington | M | 58 | 13 ans | |
Robert James Grubb | M | 44 | 9 ans | |
Gregory Winter | M | 73 |
Biosceptre International Ltd.
![]() Biosceptre International Ltd. BiotechnologyHealth Technology Part of Biosceptre (Aust) Pty Ltd., Biosceptre International Ltd. is a biopharmaceutical company based in Babraham, UK. The British company is focused on developing their BRiDGECAR™ system, which combines nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies. The company's researchers are pioneers in cancer therapeutic development, with a vision of targeted treatment for millions of cancer patients across the world. The company's multi-targeted BRiDGECAR™ system has the potential to benefit a range of malignancies and make a drastic difference to the lives of millions of cancer patients. The company's advisory board includes Sir Gregory Winter, a 2018 Nobel Prize winner in Chemistry.
Biosceptre (Aust) Pty Ltd.
![]() Biosceptre (Aust) Pty Ltd. Pharmaceuticals: MajorHealth Technology Biosceptre (Aust) Pty Ltd. develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer. The company was founded in 2000 and is headquartered in North Ryde, Australia. | 2 ans |
Stephen W. Purchase | M | - | - | |
Alan Howarth | M | 78 | 5 ans | |
J. E. Aves | M | - | - | |
Robert Glenn | M | 58 | - | |
Eric Sepkes | M | 74 | 2 ans | |
Patric Foley-Brickley | M | - | - | |
Max Royde | M | 52 | 7 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Royaume-Uni | 15 | 88,24% |
Australie | 5 | 29,41% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Andrew Walton-Green
- Réseau Personnel